Bajaj Healthcare zooms 20% as Co seeks compulsory licence for Baricitinib

The company has moved the Indian Patent Office requesting to grant a compulsory license for manufacturing & supply of Covid-19 drug "Baricitinib" (API and formulation)

Shares of Bajaj Healthcare zoomed 20 per cent and hit a new high of Rs 863.95 on the BSE in intra-day deal on Tuesday after the company announced that it has moved the Indian Patent Office requesting to grant a compulsory license for manufacturing & supply of Covid-19 drug “Baricitinib” (API and formulation). Bajaj Healthcare is a leading manufacturer of active pharmaceutical ingredients (APIs), intermediates, and formulations.

At 10:40 am, the stock was up 13 per cent at Rs 813.95 on the BSE, as compared to 0.29 per cent decline in the S&P BSE Sensex. The trading volumes on